FDA 483 OBSERVATION · #531 OF 1,000 MOST-CITED
Manufacturing Instructions and Specifications
FDA cited this observation 35 times across 35 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 4.4× the rate of the average FDA-cited firm (37.1% vs 8.3%), across 35 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
The master production and control records are deficient in that they do not include complete manufacturing and control instructions, specifications, special notations and precautions to be followed.
The master production and control records are deficient in that they do not include complete manufacturing, instructions and procedures.
The master production and control records are deficient in that they do not include complete manufacturing, control, instructions and specifications.
The master production and control records are deficient in that they do not include complete manufacturing, instructions, sampling, procedures and specifications.
The master production and control records are deficient in that they do not include complete manufacturing, control, instructions, sampling, testing, procedures, specifications, special notations and precautions.
The master production and control records are deficient in that they do not include complete instructions and procedures.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.